Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL915126 | 1.00 | MIF (0.43) | MIFSMN1; SMN2KDM4EMYCCYP1A2 | |
| SCHEMBL16993740 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4ENPC1RAB9AMAOB | |
| SCHEMBL16993737 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4ENPC1RAB9AMAOB | |
| Hydrochloric Acid SCHEMBL5703171 | 0.91 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4ENPC1RAB9AMAOB | |
| Hydrochloric Acid SCHEMBL5703165 | 0.91 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4ENPC1RAB9AMAOB | |
| Acetic Acid SCHEMBL915586 | 0.90 | SMN1; SMN2 (0.41) | MIFSMN1; SMN2KDM4EMYCCYP1A2 | |
| Acetic Acid SCHEMBL915585 | 0.90 | SMN1; SMN2 (0.41) | MIFSMN1; SMN2KDM4EMYCCYP1A2 | |
| Acetic Acid SCHEMBL917033 | 0.88 | KMT2A (0.47) | SMN1; SMN2POLBHTTMAPTNOX4 | |
| Acetic Acid SCHEMBL917031 | 0.88 | KMT2A (0.47) | SMN1; SMN2POLBHTTMAPTNOX4 | |
| Acetic Acid SCHEMBL915065 | 0.88 | KDM4E (0.50) | MIFSMN1; SMN2KDM4EMYCNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | claimed |
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2007-10-04 | — | — | US | claimed |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MELACURE THERAPEUTICS AB (SE) | 2007-04-19 | — | — | US | claimed |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2004-02-05 | — | — | US | claimed |
| EP-1313461-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | Melacure Therapeutics AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002011715-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MELACURE THERAPEUTICS AB (SE) | 2002-02-14 | — | — | WO | claimed |
| US-9227927-B2 | Method of treating inflammation | ANAMAR AB (SE) | 2016-01-05 | — | — | US | disclosed |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | disclosed |
| US-8410174-B2 | Method for treating arthritis | ANAMAR AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-8309609-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-11-13 | — | — | US | disclosed |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | ANAMAR AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-8148429-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110015437-A1 | USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2007-10-04 | — | — | US | disclosed |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MELACURE THERAPEUTICS AB (SE) | 2007-04-19 | — | — | US | disclosed |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2004-02-05 | — | — | US | disclosed |
| EP-1313461-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | Melacure Therapeutics AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002011715-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MELACURE THERAPEUTICS AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | MIF 2008/4885SMN1; SMN2 3287/4885KDM4E 2870/4885 |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | MIF 1966/4885SMN1; SMN2 3263/4885KDM4E 2898/4885 |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | MIF 2008/4885SMN1; SMN2 3287/4885KDM4E 2870/4885 |
| US-20110015437-A1 | USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MC1R, MC5R, MCHR1 | MIF 2008/4885SMN1; SMN2 3287/4885KDM4E 2870/4885 |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | MC2R, MC5R, MC1R | MIF 303/4885SMN1; SMN2 3361/4885KDM4E 3363/4885 |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | MC5R, MC1R, MC2R | MIF 1460/4885SMN1; SMN2 3068/4885KDM4E 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.